公开(公告)号：WO2023072903A1

公开(公告)日：2023-05-04

申请号：PCT/EP2022/079717

申请日：2022-10-25

申请人： HOSPITAL CLINIC DE BARCELONA ,  INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER ,  AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, M.P

发明人： CHAMORRO SÁNCHEZ, Angel ,  PLANAS OBRADORS, Ana María ,  RAMOS CABRER, Pedro

IPC分类号： A61K9/127 ,  A61K31/522 ,  A61P9/00

摘要： The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

公开(公告)号：WO2023038202A1

公开(公告)日：2023-03-16

申请号：PCT/KR2021/018780

申请日：2021-12-10

申请人： 주식회사 아울바이오

发明人： 김청주 ,  안태군 ,  김아람 ,  신현호 ,  김도희

IPC分类号： A61K9/16 ,  A61K31/522 ,  A61K9/00 ,  A61P31/20

摘要： 본 발명은 생분해성 고분자를 이용한 서방형 미립구 및 이의 제조방법에 관한 것으로, 보다 상세하게는 엔테카비어를 포함하며, 생체적합성 고분자로 이루어진 미립구 및 이의 제조방법에 관한 것이다. 본 발명에 따른 엔테카비어를 포함하는 미립구는 장기간 동안 안정한 약물 방출률을 나타내어 일정 기간 동안 혈액내에 엔테카비어를 유효 농도로 유지시킬 수 있어 약물의 투여 주기를 연장하고, 환자의 복약 순응도를 높이며, 급격한 약물 초기 방출로 인한 부작용을 경감시킬 수 있다.

公开(公告)号：WO2023280908A1

公开(公告)日：2023-01-12

申请号：PCT/EP2022/068715

申请日：2022-07-06

申请人： UNIVERSITE CLERMONT AUVERGNE ,  INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT ,  PILEJE INDUSTRIE

发明人： LAINE, Emmanuelle ,  BEYSSAC, Eric ,  DELANNE, Améline ,  GARRAIT, Ghislain ,  FADHLAOUI, Khaled ,  BARDOT, Valérie

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K47/36 ,  A61K47/42 ,  A61K47/46 ,  A23K10/37 ,  A23K20/147 ,  A23K20/163 ,  A23K50/50 ,  A23L29/231 ,  A23L29/256 ,  A23L33/105 ,  A23L33/125 ,  A23L33/17 ,  A61K35/747 ,  A61K38/17 ,  A23L33/19 ,  A23L33/21 ,  A61K36/185 ,  A61K31/522 ,  A61K31/734

摘要： La présente invention concerne une forme galénique pour la libération contrôlée d'une substance d'intérêt par voie orale, ladite forme galénique comprenant une association d'excipients polymères biodégradables et biocompatibles, ladite association d'excipients polymères comprenant au moins une protéine dénaturée ou non dénaturées, au moins un polysaccharide et de la pulpe de fruits de baobab. Elle concerne en outre une composition pharmaceutique ou alimentaire à libération contrôlée à base d'une telle forme galénique, ainsi qu'un procédé de préparation d'une telle composition.

公开(公告)号：WO2022266442A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033989

申请日：2022-06-17

申请人： PEPSICO, INC.

发明人： WANG, Yu ,  NO, DaSom ,  FANG, Yuan ,  TRUSLER, Nelson ,  BROWNE, Damian ,  ZHAO, Xin ,  TIAN, Meng ,  ZHANG, Shiyi ,  MEYER, George

IPC分类号： A61K31/522 ,  A61K47/54 ,  C08G18/32 ,  A23L33/10

摘要： The present disclosure relates to complexes comprising caffeine and tannic acid as well as emulsions and beverages comprising these complexes which slow the release of the caffeine. Also described are methods of preparing the complexes and emulsions and beverages comprising caffeine-tannic acid complexes.

公开(公告)号：WO2022261301A1

公开(公告)日：2022-12-15

申请号：PCT/US2022/032805

申请日：2022-06-09

申请人： GILEAD SCIENCES, INC.

发明人： KENNEY, Thomas, F. ,  MATSON, Clinton, K. ,  VENKATARAMANI, Chandrasekar

IPC分类号： A61K31/337 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/553 ,  A61K31/7068 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

摘要： The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.

公开(公告)号：WO2022256550A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031992

申请日：2022-06-02

申请人： TEON THERAPEUTICS, INC.

发明人： LIU, Jiwen ,  OSTOVIC, Drazen ,  KARABORNI, Sami

IPC分类号： C07D473/06 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P13/12 ,  A61P25/00 ,  A61P35/00 ,  A61K31/522

摘要： Forms of ethyl 3-ethyl-2,6-dioxo-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1,2,3,6-tetrahydro-7H-purine-7-carboxylate, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.

公开(公告)号：WO2022250977A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/029145

申请日：2022-05-13

申请人： THE TEXAS A&M UNIVERSITY SYSTEM

发明人： TSAI, Robert Y. ,  LIU, Xiaohua

IPC分类号： A61K31/165 ,  A61K31/522 ,  A61K38/12

摘要： The present disclosure provides pharmaceutical formulations comprising i) a support frame, ii) one or more bioadhesive materials, iii) a first active ingredient, and iv) a second active ingredient. The disclosure also provides methods of treating a subject using the pharmaceutical formulations for various disease states and processes for making the pharmaceutical formulation.

公开(公告)号：WO2022250692A1

公开(公告)日：2022-12-01

申请号：PCT/US2021/034818

申请日：2021-05-28

申请人： HENDERSON, Theodore

发明人： HENDERSON, Theodore

IPC分类号： A61K31/426 ,  A61K31/522 ,  A61K31/7076 ,  A61K31/708 ,  A61K45/06 ,  A61P31/12

摘要： The disclosure relates to methods for treating a virally induced functional disorder (VIFD), a functional somatic syndrome (FSS) and/or a herpes-family virus by administering a therapeutically-effective combination of an antiviral compound and nitazoxanide. The disclosure is further related to pharmaceutical compositions comprising a combination of an antiviral compound and nitazoxanide.

公开(公告)号：WO2022196818A1

公开(公告)日：2022-09-22

申请号：PCT/JP2022/012853

申请日：2022-03-18

申请人： SSP CO., LTD.

发明人： ISHIKAWA, Yasuhisa ,  KODAKA, Gento ,  UMINO, Makoto ,  ONUKI, Yoichi ,  OKADA, Minoru

IPC分类号： A61K31/135 ,  A61K31/167 ,  A61K31/192 ,  A61K31/375 ,  A61K31/4152 ,  A61K31/4402 ,  A61K31/51 ,  A61K31/522 ,  A61K31/616 ,  A61K9/28 ,  A61K9/50

摘要： Provided is a coated solid pharmaceutical preparation which not only makes it difficult to perceive the unpleasant taste and/or unpleasant odor of pharmacologically active substances when taken but also does not easily discolor over time. In the coated solid pharmaceutical preparation, a solid pharmaceutical preparation containing a pharmacologically active substance is coated with a film containing a film-forming polymer and a flaky substance.

公开(公告)号：WO2022192271A1

公开(公告)日：2022-09-15

申请号：PCT/US2022/019362

申请日：2022-03-08

申请人： LENNHAM PHARMACEUTICALS, INC.

发明人： SIPPY, Bradford, C.

IPC分类号： A61K31/522 ,  A61K36/74 ,  A61K9/08

摘要： Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.